Ignalis-M 50/1000 Tablet ER is a combination oral antidiabetic medication containing Sitagliptin 50 mg and Metformin 1000 mg in an extended-release formulation. This dual-action therapy is indicated for the management of type 2 diabetes mellitus in adult patients to improve glycemic control when diet and exercise alone are insufficient. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by increasing levels of active glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby promoting insulin release and reducing glucagon secretion in a glucose-dependent manner. Metformin, a biguanide, primarily decreases hepatic glucose production, improves insulin sensitivity, and enhances peripheral glucose uptake. The extended-release formulation of Metformin allows for once-daily dosing, improving patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release forms. Ignalis-M 50/1000 Tablet ER should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose levels. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Common adverse effects may include gastrointestinal disturbances, headache, and nasopharyngitis. Regular follow-up with healthcare providers is essential to optimize therapy and monitor for potential side effects.